Causeway International

19/02/2026

Spotlight on Causeway International at the 23𝐫𝐝 𝐏𝐡𝐚𝐫𝐦𝐚 𝐀𝐬𝐢𝐚 𝐈𝐧𝐭𝐞𝐫𝐧𝐚𝐭𝐢𝐨𝐧𝐚𝐥 𝐄𝐱𝐡𝐢𝐛𝐢𝐭𝐢𝐨𝐧!📸

We appreciate the dedication and innovation you brought to the event this year. Thank you for being a vital part of the exhibition and for helping us move the industry forward.

We can’t wait to see what you bring to the 24𝐭𝐡 𝐏𝐡𝐚𝐫𝐦𝐚 𝐀𝐬𝐢𝐚!🚀

19/02/2026

19/09/2024

Mavacamten: a first-in-class myosin inhibitor for obstructive hypertrophic cardiomyopathy - PubMed

Mavacamten is a first-in-class, targeted, cardiac-specific myosin inhibitor approved by the US Food and Drug Administration for the treatment of adults with symptomatic New York Heart Association Classes II and III obstructive hypertrophic cardiomyopathy (oHCM). Mavacamten was developed to target th...

06/09/2024

‘Gamechanging’ drug to prevent hot flushes wins approval in UK | Women's health | The Guardian

Veoza, also known as fezolinetant, is prescription-only and will be available privately from January

02/09/2024

Novel Mechanisms Set FDA-Approved Amivantamab-Lazertinib Combo Apart in NSCLC

This newest approval for amivantamab is the second approval in 6 months for the EGFR and MET bispecific antibody.

10/07/2024

Movantik (naloxegol) for the treatment of opioid-induced constipation

Movantik (naloxegol) is an opioid antagonist therapy for the treatment of opioid-induced constipation in adult patients with chronic, non-cancerous pain.

07/07/2024

Experts say Pakistan budget massively negative for struggling healthcare sector - Pakistan - Business Recorder

KARACHI: Pharmaceutical industry experts have expressed concerns regarding the recent taxation changes in Pakistan,...

05/07/2024

FDA Approves Aprocitentan for Inadequately Controlled Hypertension | tctmd.com https://www.tctmd.com/news/fda-approves-aprocitentan-inadequately-controlled-hypertension

TCTMD: the most comprehensive online resource for interventional cardiology and beyond, with news coverage spanning the entire field of cardiovascular disease.

27/06/2024

'Impressive' New Data on Novel Schizophrenia Hopeful KarXT

The novel investigational antipsychotic KarXT was effective and well tolerated in adults with schizophrenia experiencing acute psychosis in a second phase 3 trial.

01/04/2024

A Brand New Blood Pressure Drug: Tryvio (Aprocitentan) | The People's Pharmacy

Will a brand new & different blood pressure drug change the treatment of hypertension? Meet Tryvio (aprocitentan). What are the pros & cons?